CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 655 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR ¿Qué deben saber las personas con cáncer sobre el consumo de... January 11, 2022 Targeted Drug Trio Improves Survival in Colorectal Cancer with BRAF Mutations November 13, 2019 Hypogammaglobulinemia and Sars-CoV-2 Viraemia Determine COVID-19 Severity in Patients with Haematological... July 16, 2021 EMA Recommends Granting a Marketing Authorisation for Tepotinib December 23, 2021 Load more HOT NEWS ESMO Issues First Recommendations on Using Next-Generation Sequencing for Advanced Cancers... How Do Black People with Cancer View Clinical Research? EMA Recommends Granting a Marketing Authorisation for Generic Arsenic Trioxide No Survival Benefit from Adding Preoperative Chemoradiotherapy to Perioperative Chemotherapy in...
